Power3 Medical Products, Inc. has announced that its CSO, Ira L. Goldknopf, PhD. has been invited to present at the OncoProteomics World Congress in San Francisco on April 27-28, 2006.
The presentation will be entitled "Convergence of ProteomeDiagnsotics and PharmacoProteomics towards Personalized Medicine - Examples from Breast Cancer and Leukemia." Dr. Goldknopf's talk will cover the Company's dual breast cancer diagnostic platforms: 1) NAFTest™ and biomarkers and 2) blood serum test and biomarkers, as well as the Company's 3) bone marrow test, biomarkers, and therapeutic target for drug resistant and sensitive leukemia.
"We are particularly gratified that Dr. Kewal Jain, an internationally prominent thought leader on proteomics science, technologies and markets, has seen fit to feature Power3 Medical's work at such an important World Congress. We are delighted that the biotechnology community is taking notice of our efforts and accomplishments in breast cancer and drug resistant leukemia," said Dr. Goldknopf. "This invitation is a significant validation of Power3 Medical's position as a leader in advancing the science of proteomics for development of targeted diagnostics and therapeutics for cancer."
The Company is conducting ongoing clinical validation trials for their breast cancer tests and biomarkers at 3 sites, Mercy Woman's Center, a high risk breast cancer clinic in Oklahoma City, with Dr. Alan Hollingsworth, The New York University Medical Center, in New York City with Dr. David Fishman, and The Obstetric and Gynecological Associates at the Woman's Hospital in Houston with Dr. Leroy Leeds.